Eighteen months ago, pharmaceutical executives were doing the opposite of investing in Britain. Merck shelved a billion pound research centre in London. AstraZeneca paused work in Cambridge. Company after company told parliamentary committees that the UK had become an unreliable place to bring a new medicine to market, hobbled by a rebate scheme clawing back an ever larger share of sales and a cost watchdog that seemed to value new treatments below what other wealthy countries were willing to pay. That retreat has now, at least partially, reversed. The Association of the British Pharmaceutical Industry says the sector has committed an additional £2 billion to the UK since September last year, spanning AI-assisted drug discovery to large-scale manufacturing. The figure comes from a competitiveness report benchmarking Britain against twelve other major markets across more than forty measures, and it marks the clearest signal yet that government efforts to repair its relationship with an alienated industry are having some effect.

The mechanism behind the turnaround is worth dwelling on, because it is not simply a matter of ministers making warmer noises. Two specific policy changes did the work. The National Institute for Health and Care Excellence raised the baseline threshold it uses to judge whether a medicine represents good value, letting more expensive treatments clear the cost-effectiveness bar that had kept many of them off the NHS formulary. Alongside that, the government committed to lifting UK spending on innovative medicines to 0.6 per cent of GDP, a formal target rather than an aspiration. Together these amount to a promise that industry will be paid more, and more predictably, for the medicines it develops, which is precisely the kind of signal that moves investment decisions made in corporate headquarters thousands of miles away.

For the NHS, this is not simply good news wearing an economic wrapper. A higher NICE threshold and a larger share of GDP devoted to innovative medicines mean, almost by definition, a bigger medicines bill. NHS trusts already spend more than £20 billion a year on drugs, a line item that has been rising faster than overall NHS funding for years, and that squeeze does not fall evenly. Money committed to newly approved oncology or rare disease treatments does not appear from nowhere. It competes with elective recovery funding, with community services, with the unglamorous maintenance of buildings and equipment that keeps a hospital running. Health leaders who have spent the past two years managing waiting lists and workforce shortfalls under tight financial settlements will recognise the tension immediately. Every pound that flows to a pharmaceutical company as the price of restored investor confidence is a pound that has to be found somewhere inside a system that is already stretched.

There is a more optimistic reading, and it deserves to be taken seriously rather than waved away as industry spin. Faster access to new treatments can reduce costs elsewhere in the system, keeping people out of hospital, shortening the course of a disease, or replacing an expensive course of care with a single effective drug. The life sciences sector remains one of the few parts of the UK economy still capable of generating high-value jobs and export earnings at scale, and a government trying to demonstrate that growth and public services are not permanently at odds has an obvious interest in this story succeeding. The ABPI's own data on adoption should temper the enthusiasm, however. Only around a third of newly licensed medicines were made fully available for their approved use across the UK between 2021 and 2024, a lower proportion than most comparable European countries. A policy environment that persuades companies to invest is not the same as one that gets new medicines to patients quickly, and the gap between the two has been a persistent British weakness.

What happens next depends on delivery rather than announcement, which is where these figures should be read with some caution. Investment commitments can be paused as easily as they were resumed, and the ABPI's own report frames this as a fragile recovery rather than a settled one. For NHS leaders, the practical task is less about celebrating renewed industry confidence and more about ensuring that the extra medicines spending it implies is planned for, rather than absorbed as an unbudgeted shock partway through the financial year. For ministers, the harder test is whether a strategy built on rewarding pharmaceutical companies more generously can survive contact with a health service under permanent pressure to do more with what it already has. The money has started moving again. Whether the system built to receive it is ready is a separate question, and one that will not be answered by a single year's figures.

‍